NEW YORK (GenomeWeb News) – The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics today announced a collaboration to research and develop nucleic acid-based body fluid diagnostics.
As part of the five-year deal, Exosome will provide technical and development support to Mt. Sinai researchers, as well as early access to technology product upgrades. Mt. Sinai retains rights to molecular biomarkers associated with disease progression and drug response, while Exosome will retain commercial development rights for molecular in vitro diagnostic products. Further details were not disclosed.
Exosome and Mt. Sinai plan to create targeted research and biomarker discovery programs in oncology, inflammation, and other disease areas, they said. New York-based Exosome anticipates it will pursue commercial development and US Food and Drug Administration review of successful validations for in vitro diagnostics.
"As we advance our precise medicine program in the Departments of Pathology and Genomics at Mount Sinai, biofluid-based, point-in-time analyses, made possible by the Exosome Diagnostics-Mount Sinai relationship, will undoubtedly lead to an improved, patient-centric understanding of disease, thereby guiding more informed treatment decisions and response to therapy," Carlos Cordon-Cardo, chairman of the department of pathology at the Icahn School of Medicine and a member of Exosome's scientific advisory board, said in a statement.